Kirstin C. Jensen

Predictive radiogenomics modeling of EGFR mutation status in lung cancer

Chuong D. Hoang, S. Plevritis, G. Berry, 2017, Scientific Reports.

Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)

Kirstin C. Jensen, A. Gutin, V. Abkevich, 2012 .

Abstract P5-06-01: Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer

Kirstin C. Jensen, A. Gutin, V. Abkevich, 2015 .

P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.

B. Daniel, Kirstin C. Jensen, R. Carlson, 2011 .